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ABSTRACT 
Epithelial ovarian cancer (EOC) is the most lethal of gynecological cancers, and cure 
rates have improved very little in the last 30 years. The most common histological 
subtypes are serous, endometrioid, clear cell and mucinous EOC. To date, all EOC 
have been treated as one entity. However, based on epidemiological and molecular 
studies it is now clear that the different subtypes should be considered as different 
diseases. Also, low-grade serous and high-grade serous EOC (HGSOC) has distinctive 
molecular characteristics. The majority of EOCs are HGSOCs characterized by genetic 
instability, advanced stage at presentation and acquired chemoresistance. There is an 
urgent need to identify new targets in order to improve prognosis for these tumors.  
A deregulated energy metabolism is a hallmark of malignant disease that offers 
possible future targets for treatment. Its major features are an increased aerobic 
glycolysis and alterations in mitochondrial bioenergetics. This thesis aims at identifying 
prognostic and treatment predictive markers in advanced HGSOC. We specifically 
explore the expression of metabolic enzymes and heat shock protein 60 (HSP60) and 
test the chemo-potentiating effect of glycolysis inhibitor 2-deoxy-D-glucose (2-DG) in 
vitro. 
 
We found a platinum-potentiating effect of 2-DG in two EOC cell lines and 17 freshly 
isolated ascites EOC samples. We also found the ability of the mitochondrial β-F1-
ATPase:HSP60 ratio to predict sensitivity to such combination treatment. 
 
We prospectively collected fresh tumor samples from 123 patients undergoing primary 
surgery for advanced EOC. Of these, 56 met the eligibility criteria with adequate 
sample RNA yield. Ninety-three percent were high-grade tumors. We performed real-
time PCR and immunohistochemistry to study the expression of HSP60, 
glyceraldehyde-3P-dehydrogenase (GAPDH), pyruvate kinase M2 (PKM2), 
mitochondrial β-F1-ATPase (ATP5B) and the bioenergetic cellular (BEC)-index. We 
used Cox proportional hazards models to estimate overall survival (OS) and platinum-
free interval (PFI). A high HSP60 mRNA was associated with shorter OS (HR, 3.4 
95% CI 1.3-8.5) and PFI (HR, 3.3; 95% CI 1.5-7.2). At the protein level, HSP60 was 
also of independent prognostic value, with a median survival difference of 24 months 
between high- and low expressing groups. All patients with low tumor HSP60 protein 
expression responded to primary chemotherapy. High GAPDH mRNA levels (HR 2.1, 
95% CI 1.0-4.5) and low BEC-index mRNA (HR 0.47, 95% CI 0.23-0.95) were both 
independently associated with shorter PFI. 
 
We also compared the mRNA expression of metabolic markers and HSP60 in a series 
of 25 matched serous solid tumors and corresponding detached tumor cells in ascites. 
GAPDH, PKM2, ATP5B and HSP60 did not significantly differ in these respective cell 
states, indicating that further reprogramming of glycolysis or oxidative phosphorylation 
is not a prerequisite for serous cancer cell survival after detachment. 
 
This thesis validates targeting glucose metabolism for increasing treatment efficacy in 
EOC. Our findings also indicate that HSP60, GAPDH and BEC-index may, within the 
seemingly homogenous group of advanced HGSOCs, identify patients with different 
prognosis. 
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1 EPITHELIAL OVARIAN CANCER 
 
1.1 INTRODUCTION 
Ovarian tumors are a heterogeneous mixture of benign, borderline and malignant 
lesions thought to arise in the ovary. Ninety percent of malignant tumors are of 
epithelial origin, but transformation can occur also in the ovarian stroma or germ cells. 
The epithelial ovarian carcinomas (EOCs) are classified according to the WHO 
histopathological standards into different morphological subtypes, essentially including 
serous, endometrioid, clear cell, mucinous and undifferentiated tumors [1, 2]. The grade 
of differentiation has traditionally been denoted as low, intermediate or high [3]. Below 
chart, based on two large reviewed North American case series, shows the approximate 
relative frequencies of EOC subtypes [4, 5].  
 
 
 
The various subtypes of EOC are etiologically and molecularly distinct diseases, with 
different clinical presentation, prognosis and response to treatment. The high-grade 
serous carcinomas (HGSOCs) comprise the majority of cases and will be the focus of 
this thesis. This subtype often responds well to initial chemotherapy, but since it is 
usually diagnosed at an advanced stage, with a high risk of recurrence, most patients 
eventually develop treatment resistance and die of their disease. The other subtypes are 
more frequently found at an earlier stage, when prognosis is better [4, 5]. Today there is 
interest in development of subtype-stratified strategies for prognostication and 
treatment of EOC, but despite progress in the understanding of the subtype-specific 
underlying mechanisms of disease, prognosis is still poor. For the purpose of this thesis, 
the term ovarian cancer/EOC encompasses also the prognostically and 
clinicopathologically indistinguishable high-grade serous cases originating in the 
fallopian tube or peritoneum.  
EOC	  subtypes	  
serous	  high-­‐grade	  (68	  %)	  serous	  low-­‐grade	  (3	  %)	  endometrioid	  (10	  %)	  clear	  cell	  (11	  %)	  mucinous	  (3	  %)	  mixed	  /undifferentiated	  (5	  %)	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A reprogrammed energy metabolism has recently been recognized as a hallmark of 
cancer [6] offering possible future targets for treatment. However, when searching the 
literature we found no publication investigating metabolic enzymes as potential 
prognostic or treatment predictive markers in ovarian cancer. Considering the genetic 
instability of high-grade serous ovarian tumors, we hypothesized glycolytic and 
oxidative enzymes to be altered. This thesis presents the results of our work, and is to 
our knowledge the first publication on this topic.  
 
 
1.2 EPIDEMIOLOGY 
Ovarian cancer is the seventh most common malignancy in women worldwide, with an 
incidence in 2012 of 240,000 cases causing 152,000 deaths [7]. International statistics 
often include all invasive ovarian tumors, of which the epithelial carcinomas constitute 
the majority. Northern Europe has the highest incidence with 10 cases per 100,000 
women, which for Sweden translates into approximately 750 cases a year [8]. The 
Swedish ovarian cancer incidence has been decreasing, over the last decade by 2 % per 
year. This positive trend should be largely attributed the protective effect of oral 
contraception and reduced use of menopausal hormone replacement therapy.  
 
 
Figure 1. EOC incidence and mortality, Sweden 1980-2011 (NORDCAN database, 
www-dep.iarc.fr). 
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Ovarian cancer can affect women of all ages, but is rare before the age of 30. After that, 
the incidence gradually increases to peak at 43 per 100,000 Swedish women 65-74 
years old (Figure 2).  
 
 
Figure 2. EOC age-specific incidence (Sweden 2010, NORDCAN database). 
 
EOC is the deadliest of gynecological malignancies, with for Sweden a 5-year disease-
specific survival rate of 52 %. Figure 3 shows the 5-year survival rates for the Nordic 
countries 1964-2011. The high mortality rate reflects the dismal fact that the majority 
of patients present with advanced, FIGO stage II-IV disease.  
 
 
Figure 3. EOC relative survival, Nordic countries 1964-211 (NORDCAN database). 
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1.3 PATHOGENESIS 
Over 90 % of ovarian tumors are of epithelial origin. The ovarian surface epithelium is 
a single layer of phenotypically uncommitted mesothelial cells that, at the hilus, is 
continuous with the peritoneal mesothelium. During transformation, the ovarian surface 
epithelial cells can take on characteristics of Müllerian duct derived tissues, such as the 
fallopian tube, endometrium and cervix. Tumors can arise directly at the ovarian 
surface or within inclusion cysts, which are invaginations of surface epithelium into the 
ovarian stroma. In addition, a large part of the high-grade serous tumors originate in the 
distal fallopian tube (see below). Ovulation traumatizes the ovarian surface, requiring 
cyclic tissue reconstruction. This repeated process of epithelial damage, local 
inflammatory response and cellular proliferation imposes a risk of oncogenic errors 
during DNA replication. Also, the possible exposure of the fallopian tubes and ovaries 
to retrograde infections or exogenous carcinogens could further contribute to the risk of 
transformation.  
 
1.3.1 High- and low-grade serous carcinomas – HGSOC and LGSOC 
The serous carcinomas are today classified by a two-tier system into low- and high-
grade lesions [9-11]. These two subtypes are clinically and molecularly distinct 
diseases [12, 13], arising via either of two different routes, type I or type II [11, 14]. 
Type I tumors are thought to originate in inclusion cysts and to progress via a slow 
stepwise transformation of a borderline lesion into a low-grade invasive carcinoma 
(LGSOC). Type II tumors are high-grade lesions arising rapidly without a well-defined 
clinically detectable precursor. These high-grade serous carcinomas (HGSOC) can 
originate in the ovarian epithelium, but also in the epithelia of the distal fallopian tube 
or in the peritoneum [15, 16]. The relative contributions of ovarian, fallopian and 
peritoneal sites to the genesis of high-grade serous malignancies is unclear at present, 
but several studies point at the distal part of the fallopian tube as the origin in the 
majority of cases [15-17]. 
 
HGSOC 
The high-grade serous carcinomas account for almost 70 % of EOC cases. TP53 
mutations are the earliest event associated with HGSOC transformation, and p53 
dysfunction is ubiquitous for this subtype. Mutations in the TP53 gene have been 
shown in 96 % of these tumors, and in the remaining cases p53 dysfunction is caused 
by post-translational mechanisms [18, 19]. Foci of intensely p53-positive, but benign 
linear stretches of secretory cells in the tubal mucosa have been identified in 
approximately 30 % of both BRCA-positive women and controls [16]. These putative 
precursor lesions, termed p53-signatures, are significantly more frequent in tubes also 
containing a serous tubal intraepithelial carcinoma (STIC), and transitions between the 
two have been documented indicating the distal tubes as a major site of the initial high-
grade serous carcinogenic sequence [15]. Supporting this, identical TP53 mutations 
have been described in synchronous p53-signatures, STICs and HGSOCs [16, 20]. 
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The second hallmark of HGSOC is BRCA pathway dysfunction, which by the Cancer 
Genome Atlas Research Network has been shown to affect 51 % of cases [19]. 
BRCA1/2 germline mutations were in this study of 489 HGSOCs seen in 17 % and 
BRCA somatic mutations in 3 %. In another 11 %, BRCA1 was epigenetically silenced. 
Other BRCA pathway alterations were seen in EMSY (amplified in 8 %), RAD51C 
(hypermethylated in 3 %) and PTEN (deleted in 7 %). The term BRCAness has gained 
acceptance as descriptive of the defective homologous recombination DNA repair 
system that sporadic high-grade serous cancers share with tumors occurring in BRCA 
mutation carriers [21].  
Other pathways often altered in HGSOC are the retinoblastoma (RB), PI3K/Akt and 
Notch signaling cascades, which exhibit oncogenic changes in approximately 67, 45 
and 22 % of cases, respectively [19]. Amplification or copy number gain of the cell 
cycle regulator cyclin E1 gene (CCNE1) has been reported in more than 50 % of 
BRCA wild-type HGSOC [19, 22], and has been suggested to be an early event in the 
transformation of the secretory tubal mucosa [22]. 
 
The early TP53, BRCA and cyklin E1/RB pathway defects cause genomic instability, 
and HGSOC thus exhibit a pronounced degree of DNA copy number changes [12, 19]. 
The resulting gene expression alterations are many, and HGSOC is a genetically highly 
heterogeneous disease [19, 23, 24]. Thus, a model has been proposed, in which 
HGSOC evolve as a consequence of initial disruption of DNA-repair with subsequent 
chromosomal instability and segregation into molecular subtypes [12, 25]. 
 
LGSOC 
The low-grade serous carcinomas represent only 5-8 % of serous tumors [4, 9]. This 
subtype share molecular features with serous borderline tumors and 60 % of LGSOCs 
also contain areas of borderline malignant potential [10, 26]. Like their borderline 
counterparts, LGSOCs often harbor mutually exclusive mutations of the KRAS, BRAF 
or ERBB2 genes, with approximately two thirds of cases having a mutation in either 
[11, 17, 27]. All three genes are upstream regulators of the mitogen-activated protein 
kinase (MAPK), and these mutations result in consecutive activation of MAPK 
signaling and enhanced cell proliferation. TP53 mutations are uncommon in LGSOC, 
and the level of chromosomal instability is low [11, 17]. 
 
1.3.2 Endometrioid carcinomas 
Recent studies show the endometrioid tumors to comprise approximately 10 % of 
EOCs [1, 5]. This apparent reduction in proportion is due to improved morphological 
and immunocytochemical diagnostics, leading to the recognition that many tumors that 
would previously have been classified as high-grade endometrioid are, in fact, serous in 
type [1]. Above change in subtyping is also supported by global gene expression 
studies, which have not been able to separate high-grade endometrioid and serous 
tumors [1, 28]. 
Most of the endometrioid ovarian carcinomas are thought to arise via a stepwise, type I 
transformation of an endometriotic lesion [1, 17, 29, 30]. Known molecular features of 
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these tumors include frequent CTNNB1 (encoding β-catenin), PTEN, ARID1A, KRAS 
and PIK3CA mutations and microsatellite instability [1, 17, 28, 31, 32]. Low-grade 
endometrioid tumors lack TP53 mutations [17].  
 
1.3.3 Clear cell carcinomas 
Ovarian clear cell carcinomas occur with about the same frequency as the endometrioid 
subtype, thus accounting for 10-12 % of EOCs [1, 4, 5]. The prevalence in Japan is 
higher, 15-25 % [33]. Like the endometrioid tumors, the majority of clear cell cases 
originate from endometriosis [17]. Almost 50 % of clear cell EOCs exhibit mutated 
ARID1A [32, 34], and PIK3CA mutations have been found in up to 40 % of cases [33, 
35]. C-MET amplifications have also been described [36]. Clear cell EOCs are almost 
invariably TP53 wild-type and have a low level of chromosomal instability [33]. 
 
1.3.4 Mucinous carcinomas 
Primary mucinous carcinomas of the ovary account for only 3 % of EOCs [1, 4, 5]. 
This figure is lower than previously thought, which can be ascribed better radiological, 
biochemical, morphological and immunocytochemical diagnostics of metastatic 
gastrointestinal carcinomas [37]. Mucinous carcinomas arise via the stepwise type I 
model through transformation of a mucinous borderline lesion. KRAS mutations are 
common and suggested to be an early event in the evolution of these tumors [1, 38]. 
ERBB2 overexpression or amplification is seen in 15-20 % [28, 39]. 
 
 
1.4 RISK FACTORS AND PROTECTIVE FACTORS 
The strongest known risk factors for EOC are age and certain hereditary mutations, but 
reproductive history, gynecological conditions and treatments as well as life style 
factors also influence the risk of developing this disease.  
 
Risk factors 
Family history and genetic factors 
Having a single affected first-degree relative is associated with a 2- to 3-fold increased 
risk of ovarian cancer [40]. Inherited disorders account for approximately 10 % of 
EOCs, and 90 % of these are germline mutations in BRCA1 or BRCA2. Women with 
BRCA1 mutations have a 30-40 % risk of developing EOC before the age of 70 [41-
43]. The corresponding risk for BRCA2 mutation carriers is 10-20 %. There are many 
different mutations described for both genes, and the individual risk is influenced by 
which specific BRCA-mutation the family carries. BRCA-mutations particularly 
increase the risk of high-grade serous carcinomas. Lynch syndrome with mutations in 
the hereditary non-polyposis colorectal cancer DNA mismatch repair genes (MSH2, 
MLH1, PMS1 and PMS2) account for 10 % of hereditary cases, mostly of the 
endometrioid or clear cell subtypes [1, 44]. Carriers of this syndrome have a 12 % risk 
of EOC [14, 45].  
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Other high penetrance, functionally deleterious mutations have been described in the 
BRCA pathway RAD51C and D genes in families with ovarian and breast cancer [40]. 
Also, hypermethylation of RAD51C has been described in 3 % of HGSOC [19].  
Using high throughput technologies, genome-wide association studies of single-
nucleotide polymorphisms (SNPs) have found several mild penetrance gene loci 
conferring susceptibility for ovarian cancer [40, 46]. These loci all confer modest 
effects, with per SNP relative risks ranging from approximately 0.8 to 1.2 [40, 46]. For 
example, in a study of 15,604 EOC cases and 23,235 controls, a SNP in the immune 
modulatory gene IL1A (coding for interleukin 1α with activity in the NF-κΒ pathway) 
was found associated with decreased risk of clear cell ovarian cancer (OR 0.84, 95% CI 
0.76-0.93) [47].  
 
Women with BRCA1 or BRCA2 mutations or Lynch syndrome are recommended 
prophylactic surgical removal of ovaries and fallopian tubes. Prophylactic surgery 
reduces the risk for EOC, but there remains a 5 % risk of developing a primary 
peritoneal carcinoma. Screening programs for women with a family history of EOC 
have not yet been proven effective for downstaging of disease [43]. This can be 
ascribed the fact of the majority of BRCA-positive cases being HGSOCs, which 
usually, when diagnosable, have already disseminated. However, screening may be of 
value in picking up serous carcinomas when the tumor burden is less and might also 
identify other morphological subtypes before spread of disease.  
 
Endometriosis 
Endometriosis increases the risk of developing endometrioid or clear cell ovarian 
cancer, which often arise within endometriotic lesions [1, 48, 49]. Thus, in a meta-
analysis of case-control and cohort studies including 444,225 women, endometriosis 
was associated with early-stage, low-grade disease and endometrioid or clear cell 
subtypes [50]. In another pooled analysis of 13 case-control studies comprising 7,911 
women with invasive ovarian cancer, 1,907 borderline cases and 13,226 controls, self-
reported endometriosis was associated with an increased risk of clear cell (OR 3.05, 
95% CI 2.43-3.84) and endometrioid (OR 2.04, 95% CI 1.67-2.48) subtypes. No 
association was noted between endometriosis and mucinous cancers, HGSOCs or 
borderline lesions [49].   
 
Infertility and its treatment 
Multiple studies have addressed the issue of whether ovary-stimulating drugs imposes a 
risk of EOC, but results have been divergent. Thus, the risk of ovarian cancer in women 
treated with infertility drugs was recently assessed in a Cochrane review of case-control 
and cohort studies including 182,972 women [51]. In conclusion, the authors found no 
convincing evidence of an increased risk of invasive ovarian cancer with fertility drug 
treatment. However, subfertile women treated with IVF might carry an increased risk 
of borderline ovarian tumors. The few studies showing an increase in risk of EOC had a 
high risk of bias; due to retrospective design, lack of accounting for potential 
confounders and estimates based on small number of cases.  
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Hormone replacement therapy (HRT) 
Menopausal estrogen treatment, with or without the addition of progestin, increases the 
risk of ovarian cancer. In a Danish nationwide prospective cohort study of 909,946 
women, current HRT users had an EOC incidence rate ratio of 1.44 (95% CI 1.30-1.58) 
compared to never users [52]. The risk declined with time since last use, with a risk of 
0.63 (95% CI 0.41-0.96) after 6 years off treatment. The observed risk increase was not 
significantly affected by duration of hormonal treatment, estrogen only or combination 
treatment or route of administration.  
After the 2002 Women’s Health Initiative report on HRT increasing the risk of ovarian 
cancer, there has been a reduction in HRT use. Although not proving a causal role of 
hormones, the US ovarian cancer incidence has since then declined by 2.4 % per year, 
with the largest change for the endometrioid subtype [53]. In a cohort of 169,391 
women participating in the NIH-AARP Diet and Health Study, of which 849 developed 
EOC, ever use of HRT was associated with increased risk of ovarian cancer (RR 1.33, 
95% CI 1.16-1.53). When assessing the risk for respective histological subtype, an 
increased risk was observed for all EOC subtypes except for mucinous carcinomas, 
where instead a decreased risk was seen (RR 0.37, 95% CI 0.18-0.80) [54]. 
 
Perineal talc exposure 
Perineal use of talc powder (containing possible carcinogenic particles) has been 
reported to increase the risk of EOC. Accordingly, in a pooled analysis of altogether 
8,525 ovarian cancer cases and 9,859 controls, ever use of genital powder was 
associated with increased risk of EOC (OR 1.24, 95% CI 1.15-1.33) [55]. The risk 
increase was approximately the same for the serous, endometrioid and clear cell 
subtypes, while no significant association was found for development of mucinous 
tumors.  
 
Diet and body size 
To address the issue of whether women’s height and weight impacts the risk of 
developing ovarian cancer, the Collaborative Group on Epidemiological Studies of 
Ovarian Cancer recently performed a meta-analysis of data from 47 studies comprising 
25,157 women with ovarian cancer and 81,311 women without this diagnose [56]. The 
relative risk of ovarian cancer was increased with both height and body mass index 
(BMI). The adjusted risk per additional 5 cm in height was 1.07 (95% CI 1.05-1.09). 
For BMI, the relative risk for ovarian cancer differed according to HRT use. Thus, the 
relative risk of ovarian cancer per 5 kg/m2 increase in BMI was 1.10 (95% CI 1.07-
1.13) in never users and 0.95 (95% CI 0.92-0.99) in ever users of HRT. The findings 
suggest height to be a risk factor for EOC and that increased BMI among HRT never 
users also imposes risk of developing this disease.  
Another pooled analysis, performed by the Ovarian Cancer Association Consortium, 
evaluated the association between BMI and risk of EOC by histological subtype [57]. 
This study included data from 13,548 cases and 17,913 controls, and a high BMI was 
found associated with increased risk of serous borderline tumors, LGSOC, 
endometrioid and mucinous carcinomas. However, the risk of HGSOC was not 
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affected, indicating that a reduction in population BMI would not have a major impact 
on the number of EOC deaths.  
The possible relevance of the quality of fat intake has also been investigated. In a New 
England study of 1,872 cases and 1,978 controls, the findings were suggestive of a 
protective effect of omega-3 for all EOC subtypes (high intake: OR 0.79, 95% CI 0.76-
0.96), whereas greater consumption of trans-fat instead increased the risk (OR 1.30, 
95% CI 1.08-1.57) [58]. 
In a recent systematic review of 24 prospective cohort studies, each including > 200 
cases, the authors suggest no dietary factors to be consistently associated with risk of 
ovarian cancer. Thus, no significant associations were demonstrated for red meat, fiber, 
fruit, vitamin A, vitamin E, β-carotene or folate, but tea and vegetables were suggested 
as possibly protective [59]. 
 
Smoking 
In 2009, the International Agency for Research on Cancer added mucinous ovarian 
tumors to their list of tobacco-related cancers. A later comprehensive meta-analysis by 
the Collaborative Group on Epidemiological Studies of Ovarian Cancer has further 
explored the association between smoking and EOC subtypes [60]. For current vs never 
smokers, the overall relative risk of ovarian cancer was only slightly increased (RR 
1.06, 95% CI 1.01-1.11). The impact of smoking on the relative risk for mucinous 
tumors was found to be more prominent for borderline tumors (RR 2.25, 95% CI 1.91-
2.65) than for mucinous carcinomas (RR 1.49, 95% CI 1.28-1.73). The risk of 
endometrioid (RR 0.81, 95% CI 0.72-0.92) and clear cell cancer (RR 0.80, 95% CI 
0.65-0.97) was reduced, and there was no association between smoking and HGSOC.  
 
Protective factors 
Parity 
One full-term pregnancy lowers the risk of ovarian cancer by up to one third, and 
additional pregnancies reduce the risk further [45]. Also, pregnancy at a later age is 
more protective than pregnancy early in life [45]. In the NIH-AARP Diet and Health 
Study cohort of 169,391 women, parity was inversely associated with risk of all EOC 
subtypes (RR=0.71, 95% CI 0.61-0.85) [54]. The risk reduction was greatest for the 
clear cell subtype (RR=0.28, 95% CI 0.13-0.62). Compared to nulliparous women, 
parous women had a slightly reduced risk of developing a serous carcinoma (RR 0.83, 
95% CI 0.65-1.06). Similarly, in a case-control study of 1,571 women diagnosed with 
EOC and 2,100 population-based controls, having one child was protective of high-
grade carcinomas with an OR of 0.64 (95% CI 0.49-0.83) [61].  
 
Breastfeeding 
The majority of published studies suggest breastfeeding to lower the risk of ovarian 
cancer [45]. In a study of 881 cases and 1,345 controls, women who had ever breastfed 
had a 22 % reduction in risk of ovarian cancer compared to women who had never 
breastfed (OR 0.78, 95% CI 0.64-0.96) [62]. The risk reduction was greater with longer 
duration of feeding, with an 18 months average duration conferring an OR of 0.56 
(95% CI 0.32-0.98). The overall protective effect appeared greatest for the 
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endometrioid and clear cell subtypes, for which an average of at least 6 months of 
breastfeeding per child resulted in OR 0.48 (95% CI 0.27-0.87). The number of 
breastfed children was not found to significantly affect EOC risk.   
 
Oral contraception (chemoprevention) 
The protective effect of the contraceptive pill increases with duration of use, with an 
approximate 6 % risk reduction for each year [63]. In a collaborative analysis of 23,257 
ovarian cancer cases and 87,303 controls, the relative risk for ever- versus never users 
was 0.73 (95% CI 0.70-0.76). This risk reduction was found to persist for more than 30 
years after ceased use, although attenuated over time [64]. Thus, the proportional risk 
reduction per 5 years of use was 29 % (95% CI 23-34%) for use that had ceased within 
10 years, and 15 % (95% CI 9-21%) for use that had ceased 20-29 years previously. 
The authors calculate that oral contraception has already prevented some 200,000 
ovarian cancers and 100,000 deaths from this disease, and that the number of prevented 
cancers over the next few decades will rise to at least 30,000 per year. 
In the comprehensive NIH-AARP Diet and Health Study, the protective effect of oral 
contraception was restricted to the serous subtype (RR 0.69, 95% CI 0.55-0.85) [54].   
Accordingly, oral contraception can be used as chemoprevention for BRCA1/2 
mutation carriers, with odds ratios for ever- compared to never users in studies ranging 
from approximately 0.4 to 0.6 [65]. As for non-mutation carriers, the protection 
increases with duration of use. 
 
Progestins 
The progestin component of oral contraception and HRT has been suggested to confer 
protection against ovarian cancer [45]. In a systematic review of fourteen case-control 
and cohort studies, the risk imposed by menopausal estrogen-only therapy was 
compared to that of combination estrogen-progestin treatment [66]. The EOC risk after 
5 years of use was increased for both HRT alternatives, but significantly more so for 
the estrogen-only (RR 1.22, 95% CI 1.18-1.27) than for the progestin-combination 
treatment (RR 1.10, 95% CI 1.04-1.16). The authors conclude that menopausal 
estrogens increase the risk of ovarian cancer in a duration-dependent manner, and that 
the addition of progestin partially blocks this effect.  
Interestingly, the hen has a high prevalence of ovarian cancer and treatment of hens 
with progestin only has been shown to reduce their risk of ovarian cancer by as much as 
91% (RR 0.09, 95% CI 0.01-0.70) [67]. The egg production was also significantly 
reduced by treatment.   
 
Surgery 
Tubal ligation and hysterectomy each reduces the risk of ovarian cancer by 
approximately one third [45, 68]. A recent collaborative analysis of pooled data from 
10,157 cases and 13,904 controls assessed the impact of tubal ligation on the risk for 
development of the different EOC subtypes [69]. Tubal ligation was found to 
significantly reduce the risk of all subtypes, with the greatest effect on risk for 
endometrioid (OR 0.48, 95% CI 0.40-0.59) and clear cell cancers (OR 0.52, 95% CI 
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0.40-0.67). The odds ratio, after a tubal ligation, for invasive serous cancer was 0.81 
(95% CI 0.74-0.89).  
As a consequence of acknowledging the tubal fimbriae as a major contributor to the 
HGSOC cases, prophylactic salpingectomy is increasingly being discussed as an 
alternative preventive strategy for young women at high risk for ovarian cancer. 
However, there is yet no prospective data on the efficacy of bilateral salpingectomy in 
preventing EOC [70].  
 
Indetermined 
Physical activity 
There is no firm relationship between exercise and ovarian cancer risk. A cohort study 
from the Netherlands, including 62,573 women aged 55-69 years at baseline, found 
women who spent more than 2 hours a week on recreational biking or walking to have 
a reduced risk of ovarian cancer (RR 0.65, 95% CI 0.41-1.01) compared to women who 
never participated in such activity [71]. However, in the NIH-AARP Diet and Health 
Study of 148,892 women aged 50-71 years, neither physical activity nor sedentary 
behavior was associated with EOC risk, with similar findings for serous and non-serous 
subtypes [72]. 
 
Alcohol 
A few studies have explored the relevance of alcohol intake for risk of EOC. In an 
American analysis of 1,910 ovarian cancer cases and 1,989 controls, alcohol appeared 
to have a protective effect. Compared to women with no alcohol intake, women with 
any intake had a 17 % lower risk of developing ovarian cancer, but this protective 
effect was attenuated after adjustment for education and race (OR 0.89, 95% CI 0.77-
1.03) [73]. In a later pooled analysis of 5,342 cases and 10,358 controls, recent alcohol 
consumption did not significantly affect the risk of ovarian cancer [74]. 
 
NSAIDs 
Women who are consistent users of non-steroid anti-inflammatory drugs (NSAIDs) 
have been reported to have a reduced risk for developing EOC [75, 76]. However, a 
systematic Danish review of fourteen case-control and seven cohort studies, found the 
risk of invasive ovarian cancer to be only slightly reduced with use of aspirin (RR 0.88, 
95% CI 0.79-0.98), and not significantly lowered with use of non-aspirin NSAIDs (RR 
0.94, 95% CI 0.84-1.06) [77]. 
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1.5 CLINICAL PRESENTATION 
The majority of ovarian cancers are diagnosed at a late stage (stage III-IV). This is due 
to the high proportion HGSOCs, which arise rapidly with typically early dissemination 
to the peritoneum and/or pelvic and paraaortic lymph nodes. The other subtypes are 
more commonly found before spread of disease and therefore carry a better prognosis. 
Figure 4 schematically shows the EOC pattern of spread and Table 1 the 2013 FIGO 
staging of ovarian cancer [78].  
 	  
	  
 
Figure 4. EOC pattern of spread 
(from http://cancer-the-
dangerous-disease.blogspot.se). 	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Table 1. 2013 FIGO staging of ovarian cancer.  
Stage I 
 
IA 
            
 
IB 
 
 
IC 
   IC1 
   IC2 
   IC3    
  
Tumor confined to ovaries or fallopian tubes 
 
Tumor limited to one ovary/fallopian tube (capsule intact), no tumor on ovarian/fallopian tube 
surface, no malignant cells in ascites/peritoneal washings 
 
Tumor limited to both ovaries/fallopian tubes (capsules intact), no tumor on ovarian/fallopian tube 
surface, no malignant cells in ascites/peritoneal washings 
 
Tumor limited to one or both ovaries/fallopian tubes with any of the following: 
Surgical spill 
Capsule ruptured before surgery or tumor on ovarian/fallopian tube surface 
Malignant cells in ascites or peritoneal washings 
 
Stage II 
            
 
IIA 
            
IIB 
Tumor involving one or both ovaries/fallopian tubes with pelvic extension below the pelvic brim or 
primary peritoneal cancer confined to the pelvis 
 
Extension to, and/or implants on, the uterus/fallopian tubes/ovaries 
 
Extension to other pelvic intraperitoneal tissues or primary peritoneal cancer 
 
Stage III 
            
 
 
IIIA     
   IIIA1 
       IIIA1(i)               
       IIIA1(ii) 
   IIIA2 
            
IIIB 
            
 
IIIC 
Tumor involving one or both ovaries/fallopian tubes or primary peritoneal cancer with 
cytologically/histologically confirmed spread to the peritoneum outside the pelvis and/or 
retroperitoneal lymph node metastases 
 
Positive retroperitoneal lymph nodes and/or microscopic extrapelvic peritoneal metastases 
Positive retroperitoneal lymph nodes only (cytologically/histologically proven) 
Lymph node metastases ≤ 10 mm in greatest dimension 
Lymph node metastases > 10 mm in greatest dimension 
Microscopic extrapelvic peritoneal involvement with/without positive retroperitoneal lymph nodes 
 
Macroscopic extrapelvic peritoneal metastases ≤ 2 cm in greatest dimension, with/without positive 
retroperitoneal lymph nodes 
 
Extrapelvic peritoneal metastases > 2 cm in greatest dimension, with/without positive retroperitoneal 
lymph nodes 
 
Stage IV 
            
IVA 
            
IVB 
Distant metastasis (excluding peritoneal metastases) 
 
Pleural effusion, cytologically verified 
 
Parenchymal metastases and metastases to extraabdominal organs (including inguinal lymph nodes 
and lymph nodes outside the abdomen) 
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The approximate stage distribution of cases and the contribution of respective subtype 
to early (I-II) versus late (III-IV) stage disease is shown in Figure 5. It can be seen that 
serous, endometrioid and clear cell carcinomas are approximately equally represented 
among stage I-II cases, and that nearly all mucinous tumors are early stage. In late stage 
disease, the vast majority of cases are of the serous subtype [4].  
 
 
Figure 5. EOC stage distribution (A) 
and subtype distribution in early (B) 
versus late (C) stage disease. 
Adapted from QS Ovar (German 
quality assurance register) and 
Köbel et al, Int J Gynecol Pathol 
2010. 
	  
	   	  
 
Most women diagnosed with EOC have had signs of disease for some time, but these 
are often unspecific and erroneously attributed to benign, age-related conditions. 
Symptoms can be abdominal swelling, changes in bowel-function, urinary dysfunction, 
loss of appetite, fatigue and pain. When present, malignant ascites or pleural effusion is 
usually caused by the high-grade serous subtype. Stage I carcinomas are not 
uncommonly found unexpectedly at, or after, surgery for a presumed benign ovarian 
cyst. 
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1.6 TREATMENT 
1.6.1 Primary treatment 
Standard treatment for EOC consists of surgery followed by adjuvant platinum-based 
combination chemotherapy. The surgical procedure typically includes removal of the 
uterus, tubes, ovaries and omentum and excision of all visible tumor lesions. The 
staging-operation for apparent early stage disease also comprises paraaortic and pelvic 
lymphadenectomy. Surgery for advanced stage disease often requires additional skill-
demanding procedures, such as multiple bowel incisions, splenectomy and stripping of 
the peritoneal surfaces including the diaphragm. For patients with very advanced stage 
IIIC-IV disease, adequate upfront cytoreduction can be technically unfeasible. In these 
cases, 2-4 neoadjuvant courses of chemotherapy can be given to increase the possibility 
of successful surgery [79].  
 
Patients who have undergone adequate staging surgery with proven stage IA-B, grade 1 
disease have an excellent prognosis and require no further treatment. Unfortunately, 
this applies to only a small proportion of cases, whereas the great majority will receive 
chemotherapy. The current standard platinum-taxane combination treatment is based on 
two randomized controlled multicenter trials showing the cisplatin-paclitaxel 
combination to be superior to the previous standard cisplatin and cyclophosphamide. 
Thus, in the 1996 GOG 111 trial, the cisplatin-paclitaxel combination conferred a gain 
in progression-free survival (PFS) of 5 months (18 vs 13 months, HR 0.7, 95% CI 0.5-
0.8) and in overall survival (OS) of 14 months (38 vs 24 months, HR 0.6, 95% CI 0.5-
0.8) [80]. These findings were confirmed in the OV10 trial, which in 2000 reported a 
corresponding gain in PFS and OS of 4 and 10 months [81]. Subsequent studies have 
proven carboplatin to be equally effective, but less toxic than cisplatin, wherefore this 
drug has replaced the latter as standard together with paclitaxel [82, 83].  
 
Standard adjuvant chemotherapy consists of 6 courses of carboplatin-paclitaxel given 
intravenously at 3-week intervals. Possibly, the administration of 3-weekly carboplatin 
together with weekly paclitaxel can increase treatment efficacy. This dose dense 
regimen has in a Japanese phase III study of patients with stage II-IV EOC been shown 
to substantially increase PFS (median 28.2 vs 17.5 months, HR 0.71, 95% CI 0.58-
0.88) and OS (median 100.5 vs 62.2 months) when compared to the standard 3-weekly 
combination treatment [84]. The subsequent American GOG 262 trial could not verify 
this finding, but did show a 4 months gain in PFS for the dose dense regimen in the 
subgroup of patients not receiving the addition of bevacizumab [85].  
Chemotherapy can also be administered intraperitoneally. This route facilitates higher 
drug concentrations at the site of disease, but the penetration through tumor tissue is 
limited and toxicity is high. Adjuvant intraperitoneal chemotherapy can thus be 
considered only for advanced stage cases in good performance status with 
postoperative minimal residual disease. For this group of patients, several studies have 
shown the intraperitoneal (i p) administration of drug to confer a better survival than 
standard intravenous (i v) treatment [86, 87]. In the GOG 172 trial, 429 patients were 
randomized to either i v paclitaxel plus i p cisplatin followed by i p paclitaxel on day 8 
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(i p arm) or i v paclitaxel-cisplatin only (i v arm) [86]. The median survival was 
significantly longer in the i p arm (65.5 vs 49.7 months, HR 0.75, 95% CI 0.58-0.97), 
but dosing was not comparable and toxicity was high, with only 42 % of cases being 
able to complete the prescribed 6 courses of treatment. Because of its pronounced 
toxicity and heterogeneity of studies, this route of administration is not widely used in 
Sweden [88] or other European countries.  
 
At present, the decision of adjuvant chemotherapy for EOC is mainly dependent upon 
tumor stage and grade rather than subtype, but this practice is likely to change with the 
application of subtype-specific clinical trials and development of targeted therapies.  
 
1.6.2 Treatment for platinum sensitive recurrent disease 
Approximately 75 % of advanced EOC cases will relapse within 3 years [89]. 
Recurrent ovarian cancer is not curable, but treatment of a late relapse can prolong life. 
The time interval between the last course of platinum-based chemotherapy and 
recurrence is termed the platinum-free interval (PFI), and this time span guides the 
choice of further treatment. A platinum sensitive recurrence is defined as relapse at 
least 6 months after last given platinum-based treatment. These patients often respond 
to platinum compounds also in second line, with response rates increasing with longer 
PFI.  
Compared to single agent treatment, the combination of carboplatin with either 
paclitaxel, pegylated liposomal doxorubicin (PLD) or gemcitabine has been shown to 
increase at least PFS. Thus, in the ICON 4 trial, the increase in PFS for the addition of 
paclitaxel was 3 months (12 vs 9 months, HR 0.76, 95% CI 0.66-0.89) [90]. This study 
also reported a 5 months longer OS for the platinum-paclitaxel combination (29 vs 24 
months, HR 0.82, 95% CI 0.69-0.97). Similarly, in the AGO-OVAR 2.5 trial, patients 
receiving the carboplatin-gemcitabine combination had a 2.8 months longer time to 
progression than patients given single agent carboplatin (8.6 vs 5.8 months, HR 0.72, 
95% CI 0.58-0.90) [91]. The CALYPSO study, comparing the carboplatin-PLD and 
carboplatin-paclitaxel combinations, showed the two treatment alternatives to be as 
effective, but to exhibit distinctly different toxicity profiles [92]. Thus, patients 
receiving the PLD-combination experience less alopecia and neuropathy, but instead 
more thrombocytopenia, mucositis and hand-foot syndrome. An updated assessment of 
this trial has confirmed a similar median OS for the two treatment arms (33.0 months 
for the paclitaxel-combination, 30.7 months for the PLD-combination) [93].  
Above three combination alternatives are all possible treatment options for late 
relapsing disease. For women who for different reasons cannot receive platinum the 
PLD-trabectidin combination can be an alternative [94]. In clinical practice, the choice 
of specific combination becomes dependent on the individual patient’s previously 
experienced toxicities and expected side effects of respective combination.  
 
1.6.3 Treatment for platinum resistant disease 
Platinum resistant disease is defined as tumor progressing on platinum-based 
chemotherapy or recurring less than 6 months after the last administered cycle of such 
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treatment. An uncommon extreme is tumor not even initially responding to primary 
platinum-based treatment. These cases, usually with subtypes other than HGSOC, are 
termed platinum refractory.  
Chemotherapy in the platinum-resistant situation aims at palliation, wherefore quality 
of life becomes a major consideration when choosing treatment. No randomized trial 
has in this situation been able to prove polychemotherapy superior to 
monochemotherapy [89]. There are several single agent alternatives available, for 
example PLD, paclitaxel, topotecan, trabectidin and cyclophosphamide. Hormonal 
treatment can also be an option. Response rates in the platinum resistant situation are 
low, for monotherapies usually 10-15 % [89]. However, in the recent AURELIA trial, 
evaluating the addition of bevacizumab to physician’s choice of standard 
chemotherapy, the results showed an absolute 3.3 months improvement in PFS (6.7 vs 
3.4 months, HR 0.48, 95% CI 0.38-0.60) and objective response rate (27.3% vs 11.8%) 
with the addition of the antibody [95]. 
 
1.6.4 Targeting angiogenesis 
Angiogenesis, the formation of new blood vessels from pre-existing ones, is a 
prerequisite for tumor growth beyond 1-2 mm. Over the last years, several drugs 
targeting this process have been developed, and some of them are used as adjuvants in 
standard treatment of different malignancies.  
The angiogenic process promotes metastatic spread within the peritoneum and is 
associated with the formation of malignant ascites [96-98]. Its pathways are complex. 
Tumor cells release different isoforms of pro-angiogenic vascular endothelial growth 
factor (VEGF), platelet derived growth factor (PDGF) and fibroblast growth factor 
(FGF), which, through activation of endothelial cells, leads to new blood vessel 
formation (“sprouting”). Angiogenic growth factors may also induce growth of tumor 
cells per se. VEGF, PDGF and FGF exert their effects through their tyrosine kinase 
receptor counterparts, VEGFR, PDGFR and FGFR, on the surface of endothelial (or 
tumor) cells. The ligand-receptor interaction leads to receptor dimerization and 
subsequent intracellular signaling. The angiogenic growth factors thus mediate 
activation of the PI3K/Akt, JAK/STAT and MAPK signaling cascades, with resulting 
cell survival and proliferation [96, 97]. Similarly, the angiopoetin pathway, with 
angiopoetins binding to Tie receptors, also activates PI3K/Akt signaling.  
 
Bevacizumab, a monoclonal antibody targeting VEGF, has been shown to moderately 
increase PFS when given in first line EOC treatment in combination with carboplatin 
and paclitaxel. In the GOG 218 trial, the bevacizumab-chemotherapy combination 
followed by 15 months bevacizumab maintenance resulted in a PFS-increase of 3.8 
months (14.1 vs 10.3 months, HR 0.72, 95% CI 0.62-0.82) [99]. Similarly, the ICON 7 
trial showed a 2.4 months longer PFS for the addition of the antibody and subsequent 
12 months maintenance (19.8 vs 17.4 months, HR 0.87, 95% CI 0.77-0.99) [100]. The 
benefit in this setting seems to be greatest for advanced stage patients with residual 
tumor after primary surgery. Accordingly, a subgroup analysis of the ICON 7 trial did 
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show an improvement in overall survival of 7.8 months for these most advanced cases 
(36.6 vs 28.8 months, HR 0.64, 95% CI 0.48-0.85).  
Bevacizumab has also been shown to increase PFS when given together with 
carboplatin and gemcitabine in the platinum-sensitive recurrent setting. Thus, the 
OCEANS trial reported a 4 months longer PFS for the bevacizumab-combination (12.4 
vs 8.4 months, HR 0.48, 95% CI 0.39-0.60) [101]. In addition, as discussed in section 
1.6.3, this antibody has been reported to increase PFS and response rates when added to 
standard chemotherapy in the treatment of platinum-resistant disease [95].  
Overall, bevacizumab has a confirmed place in the treatment of EOC. However, 
because of lack of predictors of response, toxicity and quality of life related issues, 
there is currently no international consensus regarding the dosing and timing of this 
drug.  
 
With the exception of bevacizumab, there are yet no angiogenesis-targeting drugs in 
routine management of ovarian cancer, but several agents have been tested and there 
are many ongoing trials. For example, the AGO-OVAR 12 trial recently reported the 
addition of nintedanib, an inhibitor of angiokinase receptors VEGFR, PDGFR and 
FGFR, to somewhat increase PFS when given concomitantly in first line with 
subsequent maintenance (17.3 vs 16.6 months, HR 0.84, 95% CI 0.72-0.98) [102]. 
Pazopanib, another multi-targeted tyrosine kinase inhibitor, has also been reported to 
improve PFS when given as maintenance after completed primary treatment. Thus, in 
the AGO-OVAR 16 trial, the median PFS was 5.6 months longer in the pazopanib-arm 
(17.9 vs 12.3 months, HR 0.77, 95% CI 0.64-0.91) [103].  
 
 
1.7 RESPONSE TO TREATMENT AND PROGNOSIS – SHORT SUMMARY 
The most important predictor of survival from ovarian cancer is stage at diagnosis. The 
five-year overall survival after diagnosed EOC ranges from at least 90 % for stage IA 
cases to less than 20 % in stage IV [104]. Treatment response rates differ greatly 
between subtypes, with the majority of HGSOCs responding to standard primary 
chemotherapy. In contrast, the response rates for advanced clear cell, low-grade serous 
and mucinous carcinomas are low. For example, in one study of advanced LGSOCs 
only four percent reached a complete remission [105].  
Despite the initial high responsiveness of HGSOCs, most patients recur. Approximately 
75 % of advanced EOC cases relapse within 3 years. Along with disease recurrence and 
subsequent treatment, the tumor chemosensitivity gradually diminishes. The expected 
OS in the platinum resistant situation is less than 12 months, and only 10-20 % of these 
progressed cases respond to the drugs in use today [89].  
 
 
1.8 PROGNOSTIC AND TREATMENT PREDICTIVE MARKERS 
The word prognosis stems from the Greek pro = before and gnosis = knowledge, 
meaning the ability to foretell the course of events, e.g. after diagnose of a specific 
malignancy. The individual prognosis at any given time point is influenced by many 
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things, for example age, concomitant diseases, spread of disease and previous response 
to treatment. A prognostic marker can thus be any biologic indicator of outcome. A 
treatment predictive marker is a prognostic marker with the ability to aid in assessing 
the probability of response to a specific treatment.  
Few EOC biomarkers have been established, probably in part due to the extreme 
heterogeneity of the disease, but also because subtype-specific associations might be 
obscured in studies including all subtypes. Today, there is no routine marker guiding 
the choice of therapy for EOC. 
 
CA125 
Cancer antigen 125 (CA125) is a tumor marker widely used for detection and 
monitoring of EOC. This protein (also known as MUC16) is a surface, transmembrane 
mucin which extracellular domain can be released by proteolytic cleavage. The 
resulting plasma biomarker is unspecific in that its elevation can be caused also by 
benign conditions, such as endometriosis, inflammatory disease and postoperatively. 
An elevated serum CA125 is seen in approximately 80 % of women with advanced 
EOC [106]. HGSOC cases almost invariably exhibit increased CA125 levels, but 
mucinous cases less often do [107].  
CA125 is routinely used for monitoring the efficacy of chemotherapy and, for patients 
in remission, for detection of recurrent disease. When monitoring EOC during 
chemotherapy, CA125 has treatment predictive value. A rapid, steep decrease in 
CA125 implicates a better chance of reaching a complete remission. In contrast, an 
only slowly decreasing or stable CA125 is indicative of upcoming chemoresistance 
[108, 109]. The postoperative, pre-chemotherapy CA125 level has also been shown to 
correlate with PFS with, for the serous subtype, a 1-fold increase in CA125 being 
associated with a 7 % increase in risk of disease progression [107].  
 
Hormone receptors 
In a study performed by the Ovarian Cancer Tumor Tissue Analysis consortium, the 
expression of estrogen (ER) and progesterone (PGR) receptors were analyzed 
immunohistochemically in 2,933 EOC cases and correlated with subtype-specific 
survival [110]. A positive (weak or strong) ER or PGR expression was found 
associated with improved survival in endometrioid carcinoma (HR 0.33, 95% CI 0.21-
0.51), and a strong PGR expression was also associated with improved survival from 
HGSOC (HR 0.71, 95% CI 0.55-0.91). No significant associations were found for the 
clear cell, mucinous or LGSOC subtypes.  
 
Markers for targeted pathways 
Overexpression of VEGF and PDGF has in EOC been associated with worse outcome 
[111-113]. A recent meta-analysis of 16 studies including 1,111 ovarian cancer 
patients, found an elevated serum VEGF to be associated with poor PFS (HR 2.46, 
95% CI 1.84-3.29) [113]. Also, a subgroup analysis of studies with predominantly early 
stage cases found tumor VEGF overexpression to significantly impact PFS (HR 5.34, 
95% CI 1.95-14.59) and OS (HR 6.13, 95% CI 2.47-15.26). However, this association 
was not seen in studies with mostly advanced stage patients, in which tumor VEGF 
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expression did not notably influence outcome. Unfortunately, studies have not been 
able to show any of the angiogenic markers to reliably predict response to anti-VEGF 
treatment [114].  
 
As outlined in section 1.3.1, LGSOCs often harbor mutations in the Ras/Raf/MEK 
pathway. Studies on MEK-inhibitors in the treatment of this subtype have reached 
phase III. As regards treatment prediction, results from a phase II trial of a MEK-
inhibitor in LGSOC reported the mutation status of KRAS or BRAF not to be correlated 
with response [115]. 
 
1.8.1 HGSOC 
Patients with high-grade serous ovarian cancers can, despite having histopathologically 
indistinguishable tumors, have very different outcome. Accordingly, three 
comprehensive gene expression analyses have indicated that these tumors can be 
further subdivided into groups with distinct expression profiles predictive of prognosis 
[19, 23, 24]. In the study reported by Verhaak et al, a collaborative group used the 
dataset derived from 489 HGSOCs included in the previously reported Cancer Genome 
Atlas Research Network study [19] to develop subtype- (differentiated / 
immunoreactive / mesenchymal / proliferative) and survival (good / poor) gene 
expression signatures with the ability to predict survival [24]. The signatures were 
validated in an independent HGSOC dataset. The combination of the survival-, 
immunoreactive and mesenchymal signatures could further enhance the prognostic 
ability, with the worst outcome group (accounting for 23 % of cases) having a median 
survival of 23 months and a platinum-resistance rate of 63 % compared to a median 
survival of 46 months and a platinum-resistance rate of 23 % in other cases.  
Taken together, all three above analyses show HGSOCs with overexpression of 
immune-response genes to have a more favorable prognosis. In contrast, tumors with a 
mesenchymal gene expression pattern seem to have the worst outcome. Groups 
characterized by high expression of either genes of proliferation or differentiation have 
also been described, the latter profile with a positive prognostic impact [19, 24]. 
 
BRCA mutations 
As outlined in 1.3.1, approximately 50 % of the HGSOCs exhibit BRCA pathway 
defects [19]. Both BRCA1 and BRCA2 germline mutation carriers have been shown to 
have higher response rates to chemotherapy and improved survival compared to non-
carriers [116]. In a study including 316 HGSOCs, of which 29 were BRCA2 mutated 
(somatic or germline), BRCA2 mutation was found to predict a higher response rate 
(100 % versus 82 %) and longer OS (5-year survival rate 61% for BRCA2 mutated and 
25% for wild-type cases, HR 0.33, 95% CI 0.16-0.69) compared to BRCA1 mutated or 
wild-type cases [117]. This study did not find any association between BRCA1 
mutation status and survival. 
BRCA1 and BRCA2 take part in the homologous recombination (HR) DNA-repair 
process. BRCA dysfunction thus leads to deficient repair of DNA double-strand breaks, 
and the cell becomes dependent on alternative ways to cope with DNA damage, e.g. 
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base excision repair. Poly-ADP-ribose polymerase (PARP) is an enzyme participating 
in this repair process. Inhibition of PARP consequently renders BRCA-deficient, HR-
dysfunctional cells especially vulnerable to DNA-damaging chemotherapy. This 
concept of targeting one of the genes in a synthetic lethal pair in which the other is 
defective is termed “synthetic lethality”. Given that half of the high-grade serous 
tumors are BRCA pathway defective, PARP seems an attractive target for treatment of 
these patients, and results from phase II trials investigating PARP-inhibitors in the 
recurrent setting have been encouraging [114]. Notably, in a randomized, double-blind, 
placebo-controlled phase II study of olaparib as maintenance following response to 
platinum-based treatment of recurrent disease, the median PFS was significantly longer 
in the olaparib arm (median 8.4 vs 4.8 months, HR 0.35, 95% CI 0.25-0.49) [118]. 
Existing data suggest the BRCA mutation status to be predictive of response to PARP-
inhibitors, with the highest probability of response in BRCA germline mutation carriers 
[114, 118]. Also, immunohistochemical staining for BRCA has been shown to correlate 
well with BRCA genetic events, and could be an approach to identify patients amenable 
for such treatment [119]. 
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2 ENERGY METABOLISM IN CANCER 
Normal cells produce more than 90 % of their adenosine 5’-triphosphate (ATP) via 
oxidative phosphorylation in the mitochondria, but tumor cells utilize their metabolic 
pathways differently. Even under normoxic conditions, cancer cells often exhibit 
increased glucose consumption and lactate production alongside a decreased oxidative 
phosphorylation. This altered metabolic phenotype of malignancy was described by 
Otto Warburg already in the 1920s, and has been termed “the Warburg effect”. The 
glucose avidity of cancer has long been exploited for positron emission tomography 
(PET) imaging, where tumors are detected using the radiolabeled glucose analog 18F-
deoxyglucose (FDG).  
 
In recent years, the understanding of the malignant cell’s complex use of fuel has 
gradually become more detailed, and this reprogrammed energy metabolism has been 
proposed as an eighth hallmark of cancer [6]. Its major features are an increased 
aerobic glycolysis, tumor- and nutrient dependent alterations in mitochondrial 
bioenergetics and increased fat-metabolism (Figure 6). The mitochondrial changes 
include a truncated TCA cycle with an increased use of glutamine/serine as substrate 
and a reduced oxidative phosphorylation [120, 121]. These metabolic pathway 
alterations offer several possible targets for future cancer treatment, but they are 
believed to be dependent upon tumor type-specific activation of oncogenes and local 
oxygen- and nutrient availability and thus variable along with tumor progression [121, 
122].  
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Figure 6. Metabolic features of the malignant cell. Important substrates in red boxes, 
anabolic end products in green (adapted from AJ Levine et al, Science 2010, reprinted 
with permission). 
 
 
2.1.1 Glycolysis 
Glycolysis is the cytosolic stepwise enzymatic process of converting glucose to 
pyruvate and ATP (Figure 7). It does not require or consume oxygen. The terms 
“aerobic” and “anaerobic” glycolysis refers only to whether this degradation of glucose 
occurs in the presence or absence of oxygen. Metabolizing one glucose molecule 
through glycolysis generates only two ATP molecules, whereas its complete oxidation 
through oxidative phosphorylation renders 36 ATP. Why do cancer cells, with an 
obvious great need for energy, use such a wasteful form of metabolism? Although the 
ATP yield per consumed glucose is low, the glycolytic flux in malignant cells can be so 
high that the amount ATP produced exceeds that from oxidative phosphorylation [120]. 
Also, proliferating cells have important metabolic requirements extending beyond the 
production of ATP. By redirecting glycolytic intermediates to either the pentose 
phosphate pathway for nucleotide production or to synthesis of amino acids and 
phospholipids, the tumor cell can sustain proliferation. The cancer cell thus diverts 
about 10 % of its glucose uptake upstream of pyruvate to generate biomass [123].  
    
  24 
 
Figure 7. Glycolysis. Important regulated enzymes in green. 
 
Hexokinase  
Hexokinase (HK) facilitates the first step of glycolysis, using ATP to phosphorylate 
glucose. Inhibitors of HK, i.e. 2-deoxyglucose (2-DG), 3-bromopyruvate and 
lonidamine, have in preclinical studies been shown to have chemo-potentiating effects 
[124-126]. 2-DG is a competitive inhibitor of HK, blocking access of glucose to the 
enzyme. HK thus phosphorylates 2-DG, which then cannot be further metabolized and 
becomes trapped within the cell. This leads to accumulation of 2-DG-P and cellular 
depletion of ATP. 
 
Glyceraldehyde 3-P dehydrogenase  
Glyceraldehyde 3-P dehydrogenase (GAPDH) performs its catalytic reaction in the 
presence of nicotinamide adenine dinucleotide (NAD+) and inorganic phosphate, and 
mediates formation of NADH, contributing to the cellular redox balance. GAPDH thus 
plays an important role in protecting the cell from free radical or ROS-mediated 
damage [127]. Its glycolytic activity is repressed by oxidative stress, which thus 
increases flux through the pentose phosphate pathway generating NADPH, the cells 
reducing power to protect from oxidative damage. GAPDH was once considered a 
simple “housekeeping” protein, but recent insight into its functions reveals a 
multifaceted molecule participating in various cellular processes, also within the 
nucleus [128, 129].  
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Pyruvate kinase  
Pyruvate kinase (PK) catalyzes the final step of glycolysis and is one of its key 
regulators. There are four tissue-specific isoforms of this enzyme of which PKM2 is the 
one predominately expressed in proliferating cells [130]. PKM2 form dimers and 
tetramers, of which the tetramers are the more glycolytically active, favoring pyruvate-
production. The dimeric form is less active, causing accumulation of upstream 
glycolytic intermediates. Thus, in cancer cells, the ratio between the tetrameric and 
dimeric forms of PKM2 determines whether glucose is used for energy or anabolic 
precursors. This tetramer:dimer ratio is regulated by nutrient availability, different 
oncoproteins and reactive oxygen species [130, 131]. Like GAPDH, PKM2 also has 
additional, non-glycolytic functions. In its dimeric form, it can translocate to the 
nucleus, where it acts as a protein kinase supporting cell proliferation [130].  
 
Malignant regulation of glycolysis 
In malignant cells, transcription of glycolytic enzymes is initiated by transcription 
factors Ras, c-Myc and hypoxia inducible factor (HIF)-1α [120, 122, 132]. Hypoxia in 
the tumor microenvironment stabilizes HIF-1α, further promoting glycolytic activity. 
Another major stimulator of glycolysis is the PI3K-Akt-mTOR pathway, which 
enhances glucose uptake and up-regulates glycolytic enzymes; both by direct 
transcriptional activation and via induction of HIF-1α and c-Myc [120, 130, 132]. Akt 
also activates glycolytic enzymes by phosphorylation [132].  
The tumor-suppressor p53 has an inhibitory effect on glycolysis and instead up-
regulates cytochrome c oxidase 2 of the electron transport chain favoring oxidative 
phosphorylation [132]. Loss of p53 thus shifts metabolism from mitochondrial 
respiration towards glycolysis.  
 
2.1.2 Oxidative phosphorylation 
Oxidative phosphorylation is an electrochemically driven process taking place over the 
inner mitochondrial membrane (Figure 8). Its key enzyme is H+-ATP synthase, which 
functions as a rotary engine to produce large amounts of ATP. β-F1-ATPase (ATP5B) 
is the catalytic β-subunit of H+-ATP synthase, and rate-limiting component for ATP 
production. ATP5B is both pre- and post-transcriptionally regulated [133]. Thus, 
transcriptional repression by hypermethylation of the ATP5B gene has been described. 
However, the major regulation of ATP5B is thought to occur post-transcriptionally, 
with the Ras-GAP SH3-binding protein 1 (G3BP1) binding the ATP5B mRNA 
transcript, thus hindering its translation and resulting in cytosolic sequestration of the 
transcripts.  
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Figure 8. Oxidative phosphorylation over the inner mitochondrial membrane (from 
http://edu.docdat.com). 
 
2.1.3 Metabolic markers 
2.1.3.1 GAPDH 
The glycolytic enzymes are generally upregulated in cancer [122, 134]. As a prognostic 
marker, GAPDH has not been extensively studied. A high GAPDH has, however, been 
associated with relapse and poor survival in breast cancer [135-137]. In a study of 404 
breast cancer patients, enhanced GAPDH mRNA expression was inversely correlated 
to estrogen and progesterone receptor status, young age and grading [137]. Thus, 
GAPDH seemingly reflects breast tumor aggressiveness. Likewise, in a study of 82 non 
small cell lung cancer (NSCLC) patients, a high GAPDH mRNA expression was found 
to predict shorter survival [138]. The authors validated their findings using six 
microarray datasets including 1,250 NSCLC patients, and were able to confirm the 
prognostic impact of GAPDH in this disease.  
 
2.1.3.2 PKM2 
PKM2 overexpression has also been reported to indicate poor prognosis. In a study of 
60 colorectal cancers, PKM2 was found associated with advanced stage [139]. Also, 
PKM2 overexpression by immunohistochemistry has been shown to independently 
predict shorter survival in esophageal squamous cell cancer [140] and cancer of the 
gallbladder [141].  
 
2.1.3.3 ATP5B 
Studies on β-F1-ATPase (ATP5B) expression in cancer are few, and with apparently 
diverging results. Its down-regulation has been associated with shorter survival in colon 
cancer [142, 143]. However, in one study in breast cancer, a high β-F1-ATPase 
conferred worse survival [136].  
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2.1.3.4 BEC-index 
In 2002, Cuezva and coworkers proposed a bioenergetic cellular (BEC) index as 
prognostic in cancer [142]. This index is a ratio comparing an oxidative mitochondrial 
index with the cellular glycolytic potential. The mitochondrial part of the index (its 
numerator) consists of the ratio of the protein levels of β-F1-ATPase to mitochondrial 
chaperone heat shock protein 60 (HSP60). The cellular glycolytic potential (the BEC-
index denominator) is represented by GAPDH protein expression.  
 
mitochondrial index β-F1-ATPase / HSP60  
 ----------------------------  =  BEC-index 
glycolytic potential GAPDH  
 
Thus reflecting a shift towards higher glycolytic dependence, a low BEC-value has 
been shown to predict shorter survival in colon, lung and breast carcinomas [136, 142, 
144]. Neither the BEC-index, nor its metabolic component markers, has been 
previously studied as prognosticators in ovarian cancer. 
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3 AIMS OF THE THESIS 
 
The overall aim of this thesis was to study metabolic markers in advanced serous 
ovarian cancer, with specific focus on their significance for prognosis, treatment 
prediction and tumor progression.  
 
I. To examine the chemopotentiating effect of glycolysis inhibitor 2-deoxy-Δ-
glucose (2-DG) in ovarian carcinoma cell lines and ovarian cancer cells 
from ascites and to investigate potential treatment predictive markers for 
sensitivity to this strategy. 
 
II. To investigate the prognostic and treatment predictive value of HSP60 in 
advanced serous ovarian cancer. 
 
III. To investigate the prognostic value of glycolytic enzymes GAPDH and 
PKM2, mitochondrial β-F1-ATPase (ATP5B) and the bioenergetic cellular 
(BEC) index in advanced serous ovarian cancer. 
 
IV. To study potential differences in mRNA expression of glycolytic enzymes 
GAPDH and PKM2, mitochondrial ATP5B and HSP60 in solid tumor 
versus ascites. 
  29 
4 PATIENTS AND METHODS 
 
4.1 PATIENTS AND MATERIALS 
 
4.1.1 PAPER I 
The study material in paper I consists of two ovarian cancer cell lines, SKOV-3 and 
CaOv-4, and freshly isolated ascites tumor cells from 17 EOC cases. The initial reports 
on SKOV-3 and CaOv-4 does not specify their respective subtype, but the former is 
regarded of clear cell origin (PIK3CA- and ARID1A mutated, TP53 wild-type) and the 
latter is likely from a serous carcinoma (TP53 mutated, MYC amplified) [145]. Clinical 
data were available for 15 of the 17 ascites cases, and is briefly presented in Table 2. 
Ascites samples were collected between September 2007 and July 2008, either at 
primary surgery or at later palliative laparocentesis.  
 
Table 2. Characteristics of ascites cases (paper I). 
Case no. Stage at 
diagnosis 
Subtype Number of previous chemotherapy regimens 
1 IV HGSOC 0 (sampling cycle 1) 
2 IIIC HGSOC 0 (chemonaïve) 
3 IIIC HGSOC 5 (platinum resistant) 
4 IIIC HGSOC 0 (chemonaïve) 
5 IIIC LGSOC 0 (chemonaïve) 
6 IIIC HGSOC 0 (chemonaïve) 
7 IIIC HGSOC 0 (chemonaïve) 
8 IIIC HGSOC 0 (chemonaïve) 
9 IC HGSOC 0 (chemonaïve) 
10 IIIC HGSOC 0 (chemonaïve) 
11 IC HGSOC 7 (platinum resistant) 
12 IV HGSOC 3 (platinum resistant) 
13 IIIC HGSOC 0 (chemonaïve) 
14 IIIC HGSOC 0 (sampling cycle 1, later defined platinum refractory) 
15 IIIC HGSOC 0 (chemonaïve) 
 
 
4.1.2 PAPERS II AND III 
We prospectively collected fresh tumor samples (solid tumor and, if present, ascites) 
from 123 patients undergoing primary surgery. Of these, 57 met the eligibility criteria; 
stage IIC-IV, serous or endometrioid subtype and specimens containing at least 50 % 
tumor cells. Patients also had to receive platinum-based chemotherapy. An adequate 
quantity (≥ 1.5 µg) RNA could be extracted in all but one case. The resultant study 
population thus consists of 56 patients (dark blue in Figure 9).  
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Figure 9. 123 patients consented to participate in the study. Study cohort for papers II 
and III in dark blue. Subgroup constituting the paper IV study cohort in red. 
 
Patients were operated at the Karolinska University Hospital (Solna or Huddinge) 
between April 2003 and July 2008. Clinical data were prospectively collected in case 
report forms. Patient characteristics are summarized in Table 3. Of the included 56 
overall poor prognosis cases, 89 % had stage IIIC-IV disease. Eighty-six percent of 
tumors were diagnosed as serous, and 93 % were grade 2-3. In 70 %, the postoperative 
tumor residuals measured at least 10 mm. Patients with residual tumor at start of 
chemotherapy were considered evaluable for response, and response assessment was 
done according to modified RECIST- and GCIG criteria. Eighty-two percent responded 
to platinum-based primary treatment, but 45 % relapsed within six months with a 
median PFI of only 7.2 months and a median survival of 34.6 months. At study closure, 
19 patients (34 %) were alive, with no evidence of disease in 9 cases (16 %). Median 
follow-up was 60 months. 
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Table 3. Patient characteristics. 
Characteristic	   n	  	  
Age	  at	  diagnosis	  (years)	  	  	  	  Median	  64.5	   	  NA	  
Diagnosis	  	  	  	  Epithelial	  ovarian	  	  	  	  Fallopian	  tube	  	  	  	  Peritoneal	  
	  43	  (77	  %)	  10	  (18	  %)	  3	  (5	  %)	  
FIGO	  stage	  	  	  	  IIC-­‐IIIB	  	  	  	  IIIC	  	  	  	  IV	  
	  6	  (11	  %)	  43	  (77	  %)	  7	  (12	  %)	  
Subtype	  	  	  	  Serous	  	  	  	  Endometrioid	   	  48	  (86	  %)	  8	  (14	  %)	  
Grade	  of	  differentiationa	  	  	  	  High	  	  	  	  Moderate	  	  	  	  Poor	  
	  4	  (7	  %)	  4	  (7	  %)	  48	  (86	  %)	  
Postoperative	  residual	  tumor	  size	  	  	  	  0	  mm	  	  	  	  1-­‐10	  mm	  	  	  	  >	  10	  mm	  
	  7	  (12	  %)	  10	  (18	  %)	  39	  (70	  %)	  
1st	  line	  chemotherapy	  	  	  	  Carboplatin	  +	  Paclitaxel	  	  	  	  Other	  platinum	  based	  	  
	  49	  (88	  %)	  7	  (12	  %)	  
Response	  at	  end	  of	  treatmentb	  	  	  	  CR	  	  	  	  PR	  	  	  	  SD	  	  	  	  PD	  	  
	  24	  (49	  %)	  16	  (33	  %)	  4	  (8	  %)	  5	  (10	  %)	  
Time	  from	  EOT	  to	  recurrence/	  progression	  	  	  	  <	  6	  months	  	  	  	  ≥	  6	  months	  	  	  	  Unknown	  	  
	   25	  (45	  %)	  30	  (54	  %)	  1	  (2	  %)	  
Survival	  	  	  	  Alive,	  no	  evidence	  of	  disease	  	  	  	  Alive,	  with	  disease	  	  	  	  Death	  from	  disease	  	  	  	  Death	  from	  other	  cause	  	  
	  9	  (16	  %)	  10	  (18	  %)	  36	  (64	  %)	  1	  (2	  %)	  
Abbreviations: NA=not applicable, FIGO=federation Internationale de Gynecologie et 
d’Obstetrique, EOT=end of treatment, CR=complete response, PR=partial response, SD=stable 
disease, PD=progressive disease. 
aGrade of differentiation according to WHO international standards. 
bResponse evaluation only in cases with residual tumor at start of chemotherapy (n=49). 
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4.1.3 PAPER IV 
Within above described patient cohort, we prospectively collected tumor biopsies and 
corresponding ascites from 40 women undergoing primary surgery for suspected 
advanced ovarian cancer (Figure 9). Of these, 25 had stage III-IV disease of the serous 
(24) or endometrioid (1) subtype with solid and ascites samples containing at least 50 
% tumor cells with adequate mRNA yield. These 25 patients thus constitute the paper 
IV study cohort (red in Figure 9). All but two patients (92 %) had type II disease.  
 
The ethics committee at Karolinska Institutet, Stockholm, approved the respective 
study (paper I-IV). 
 
 
4.2 METHODS 
 
4.2.1 PAPER I 
4.2.1.1 Cell separation and treatment 
Tumor cells from fresh ascites were pelleted, resuspended in PBS and then separated 
using the Lymphoprep™ (Axis-Shield, Oslo, Norway) density gradient method [146]. 
The separation was thus done over a 3-layer discontinuous gradient consisting of (from 
the bottom): Lymphoprep, Lymphoprep / Krebs HEPES Ringer solution 3:1 and 
Lymphoprep / Krebs HEPES Ringer solution 1:2. After centrifugation, tumor cells 
were collected at the interphase between the top and middle layers, washed with PBS 
and plated.  
All cells were cultured in RPMI 1640 with supplements and kept at +37°C in 5% CO2. 
Cells were treated for 24 (apoptosis experiments) or 48 hours with either platinum (cis- 
or carboplatin), 2-DG (Sigma-Aldrich, Stockholm, Sweden) or a combination of the 
two. 2-DG competes with glucose for phosphorylation by hexokinase, the first enzyme 
of glycolysis, but is not further metabolized and becomes trapped within the cell. Drug 
doses for cis- and carboplatin were 1-20 and 16-160 µM, respectively, and for 2-DG 1-
10 mM.  
 
4.2.1.2 Assaying cell survival, apoptosis and metabolic characteristics 
We used the Sulforhodamine B-based TOX6® assay (SRB, Sigma-Aldrich, Stockholm, 
Sweden) to at different timepoints study cell survival, including regrowth capacity after 
treatment (48 h drug treatment followed by 72 h in drug-free medium). Briefly, cells 
were seeded in 96-well plates and, after over-night incubation, drugs were added in 
fresh medium. At above timepoints, adherent (still viable) cells were fixed in the wells 
by addition of trichloroacetic acid followed by 1h incubation at +4°C. Fixed cells were 
stained with sulforhodamine B dye before assessment at absorbance 565 nm minus 
background. Survival was thus measured as post-treatment remaining cellular protein 
and expressed as proportion of protein compared to control samples. Concentrations of 
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drugs causing a 50 % reduction in survival (half maximal inhibitory concentrations, 
IC50) after 48 h treatment were calculated.  
Apoptosis was assessed after 24 hours using the M30 Apoptosense® assay (Peviva, 
Sundbyberg, Sweden), which specifically detects caspase-3/caspase-7 cleaved 
cytokeratin-30 fragments in total cell lysates. This method is based upon antibody-
detection of a neopeptide formed by caspase-cleavage of cytokeratin 18. These 
fragments are stable, wherefore the assay in effect quantitates accumulated apoptosis. 
The protein expression of GAPDH, β-F1-ATPase and HSP60 was assayed by Western 
blotting and, based on densitometric analyses of the blots, BEC-index values were 
calculated as described in 2.1.3.4. Observed signals in SKOV-3 were used for 
normalization of the signals in ascites tumor cells. Cell line glucose consumption was 
assessed as 18F-deoxyglucose uptake in the presence or absence of glucose and lactate 
levels were measured in supernatants.  
 
4.2.2 PAPERS II, III and IV 
4.2.2.1 Tumor sample collection and processing 
At surgery, tumors were immediately transported on ice to the Unit for Pathology, 
where representative tumor wedge- or core biopsies were taken and imprints made 
before immersing the biopsies in RNAlater®. The specimens were then directly 
transported to the lab, where they were stored at 4° for up to 72 hours before RNA 
extraction. Ascites samples were collected in 2 x 50 ml tubes, and separated using 
Lymphoprep™ (see section 4.2.1.1) upon arrival at the lab. All tumor handling data 
were prospectively collected using tissue sample worksheets.  
 
Solid tumor imprints and ascites cytospin preparations were used for pathological 
evaluation of tumor cell proportion, and only samples with ≥ 50 % tumor cells were 
included in the study. We used the RNeasy® Midi Kit (Qiagen, Hilden, Germany) for 
RNA extraction and RNA quality and quantity was checked using Bioanalyzer 2100 
(Agilent Technologies, Santa Clara, CA). First-strand cDNA synthesis was performed 
by Superscript™ III reverse transcriptase (Invitrogene AB, Stockholm, Sweden).  
 
4.2.2.2 Real-time PCR (papers II, III and IV) 
Amplification reactions were done on the ABI 7500 system (Applied Biosystems, 
Stockholm, Sweden). We chose SYBR Green™ for detection of transcribed genes. 
Relative quantity expression values were calculated by the ΔΔCt method. The Ct value 
is the PCR cycle number at which the increase in fluorescence crosses a set threshold. 
The ΔΔCt value is the difference between the Ct value of the gene of interest and 
control, after correction for loading control (=reference genes). Samples were run in 
duplicates, and only reproducible amplification curves were further analyzed. HPRT1 
(hypoxanthine guanine phosphoribosyltransferase 1) and Β2-microglobulin served as 
reference genes, and we used Universal Human Reference RNA (Stratagene, Santa 
Clara, CA, from 10 pooled tumor cell lines) as positive control. 
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4.2.2.3 Immunohistochemistry (papers II and III) 
Formalin-fixed, paraffin embedded tissue blocks could be obtained in 54 of the 56 
cases. Four µm tumor sections were deparaffinized and rehydrated in xylene and 
graded alcohols. We used the Vectastain Elite ABC kit (Vector Laboratories, 
Burlingame, CA) for staining. For antigen retrieval, sections were heated in a 
microwave oven in citrate buffer for 20 min. After addition of primary antibodies, 
slides were incubated overnight at 8°. Sections were then incubated with secondary 
antibody before addition of the avidin-biotinylated peroxidase complex. Slides were 
developed with diaminobenzidine chromogen and counterstained with Mayer’s 
haematoxylin. We obtained negative controls by omission of the primary antibody. 
Positive controls were from breast- (HSP60, GAPDH and PKM2) and colon (ATP5B) 
carcinomas.  
Three observers, blinded for clinical outcome, independently evaluated all slides by 
assessing the whole tumor area. The maximum staining intensity of tumor cells was 
scored 0-3+, and the proportion of cells thus stained estimated. Cases were 
dichotomized into low and high expressing groups with arbitrarily set cut-offs as 
follows; HSP60: high expression: ≥ 30 % of tumor cells staining 3+, GAPDH: high 
expression: ≥ 50 % staining 2+ or any proportion staining 3+, PKM2: high expression: 
≥ 20 % staining 3+, ATP5B: high expression: any proportion staining 3+. Inter-
observer discrepancies were found for up to 15 % of examined slides, in which cases 
consensus was reached on further review. 
 
 
4.3 STATISTICS 
 
4.3.1 PAPER I 
We used the Student’s t test for determination of statistical significant differences in 
treatment effects and the Mann-Whitney U test for analysis of the treatment predictive 
value of the β-F1-ATPase:HSP60 ratio and BEC-index for potentiation by 2-DG. 
 
4.3.2 PAPER II AND III 
We estimated the platinum-free interval (PFI) and overall survival by Kaplan-Meier 
curves. Assessment of each marker’s value as independent prognosticator was done by 
Cox proportional hazards regression models, adjusted for standard confounding risk 
factors age, stage, grade and postoperative residual tumor. Fisher’s exact test was used 
for evaluating the impact of HSP60 on response.  
 
For comparative analyses of quantitative real-time PCR results, we divided cases into 
three equally sized groups according to their relative quantity of mRNA expression. 
The choice of splitting the material into three groups was made because, in a small 
material with a lesser chance of significant findings, it enables evaluation of possible 
trends. Also, in our poor-prognosis patient cohort, one third of cases equalized the 
proportion alive at end of study. 
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For analyses of GAPDH, PKM2 and ATP5B mRNA data, the group with lowest 
expression (one third of patients) was compared to cases with higher expression. The 
merging of the two thirds of cases with higher mRNA was made because their 
expression seemingly did not differ. The BEC-index was calculated, at the mRNA 
level, as outlined in section 2.1.3.4. The third of cases with the highest BEC-index 
value was compared to cases with lower values.  
 
Since IHC is a relatively insensitive, semi-quantitative method with risk of 
misclassification, we chose to stop at two groups for comparison of protein expression 
results. Thus, for all studied protein markers, statistical analyses were made after 
dichotomizing cases into low- and high expression groups.  
 
4.3.3 PAPER IV 
In paper IV, the real-time PCR expression value for respective solid tumor was 
pairwise compared to the corresponding expression in ascites using the Wilcoxon 
matched pairs signed rank sum test. This non-parametric test is well suited for 
comparisons of paired observations when the sample size is small and when there is 
risk of a skewed distribution. 
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5 RESULTS, DISCUSSION AND CONCLUSIONS 
 
5.1 PAPER I 
Ovarian carcinoma cells with low levels of β-F1-ATPase are sensitive to combined 
platinum and 2-deoxy-Δ-glucose treatment 
 
5.1.1 Cell lines 
CaOv-4 cells were more resistant to platinum drugs than SKOV-3 cells (cisplatin IC50 
of 35 and 12 µM, respectively), but more sensitive to potentiation by 2-DG. The 2-DG-
mediated decrease in IC50 was thus greatest for CaOv-4 cells, where co-treatment with 
2-DG at 5 and 10 mM reduced the cisplatin IC50 from 35 to 14 and 5 µM, respectively. 
 
To investigate the regrowth capacity after low-dose platinum ± 2-DG, cells were first 
treated with drugs for 48 hours and then allowed to recuperate for 72 hours in fresh, 
drug-free medium. After release from drug, cells treated with either platinum or 2-DG 
resumed growth, but the combination-treated cells did not. Thus, the 2-DG-platinum 
combination seems to have irreversible antiproliferative effects, see Figure 10.  
 
 
	  
Figure 10. Regrowth 
capacity of SKOV-3 cells 
after treatment with low-
dose cisplatin or 
carboplatin ± 2-DG. Cell 
survival assessed after 48 
h of drug treatment and 
after a further 72 h in 
drug-free medium.	  
 
The cell lines’ BEC-indices, based on digital scanning of Western blots, were 0.09 for 
SKOV-3 and 0.03 for CaOv-4, suggesting a higher glycolytic activity in CaOv-4. This 
was verified by assessments of glucose uptake and lactate production, which was 
approximately twice as high in CaOv-4 compared to SKOV-3 cells.  
 
5.1.2 Tumor cells from ascites 
Treatment of ascites tumor cells with 2-DG alone caused a 0-50 % reduction in survival 
with an IC50 of < 20 mM in 6 of the 17 samples. The median cisplatin IC50 was 23 µM. 
After elimination of five carboplatin-resistant outliers, the median IC50 was 282 µM for 
this compound. Combination treatment with cisplatin and 5 mM 2-DG did in all 
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samples cause a reduction in cisplatin IC50, with a median decrease of 68 %. In 
contrast, 2-DG potentiated responses to carboplatin in only 7 of 17 samples.  
 
Acute apoptosis was assessed after 24 hours of treatment. Carboplatin-induced 
apoptosis was generally not potentiated. For the cisplatin-2-DG combination, 
potentiation of apoptosis was seen in some samples, but not in all (despite all samples 
showing a 2-DG-mediated reduction in IC50). We therefore conclude that although 2-
DG may increase cisplatin-induced apoptosis, this is not the only mode of potentiation.  
 
To test the possible ability of the BEC-index to predict 2-DG-potentiation of cisplatin, 
the ascites cases were dichotomized according to the percentage decrease in cisplatin 
IC50 induced by 2-DG. Samples with a greater than 50 % reduction were designated 
highly potentiated, and compared to less potentiated samples. The BEC-index values of 
the highly potentiated group were homogeneously low, but did not in this small 
material differ significantly from the less potentiated group. However, the BEC-index 
numerator ratio β-F1-ATPase:HSP60 was found to predict sensitivity to 2-DG-
mediated potentiation of cisplatin (p=0.028).  
 
5.1.3 Discussion and conclusions 
The 2-DG-mediated increased platinum-efficiency demonstrated in this study seems to 
be more pronounced for the cisplatin- compared to the carboplatin-combination. This 
might in part be due to the different molecular effects induced by the two drugs, where 
cisplatin is a more highly reactive molecule inducing a greater degree of acute 
apoptosis than carboplatin [147]. Cisplatin also bind directly to mitochondrial DNA 
and proteins, including the voltage-dependent anion channel protein, which couples 
metabolic processes between the cytosol and mitochondria [148]. A thus impaired 
oxidative phosphorylation could render the cell more dependent on glycolysis, and 
thereby particularly susceptible to glycolysis-inhibition. Also, one must consider that a 
proportion of the patients providing the ascites samples had been previously exposed to 
carboplatin-based chemotherapy, wherefore a specific resistance to this drug cannot be 
excluded. 
The cell line experiments over longer time with low-dose combination treatment and 
subsequent regrowth in fresh medium did, however, show similar results for both 
platinum compounds. Thus, the total antiproliferative effect is different from the acute 
apoptotic response, with the addition of 2-DG also affecting subsequent recuperation 
capacity of surviving tumor cells.  
 
Targeting malignant cell glycolysis is attracting interest as a novel therapeutic strategy 
in cancer [127]. Several small molecule agents inhibiting various glycolytic enzymes 
are being investigated. 2-DG is the most studied, and this agent has in preclinical 
studies of various malignancies been shown to significantly increase the efficacy of 
concomitant chemo- or radiotherapy [149]. For example, 2-DG has in vivo been shown 
to potentiate the effect of adriamycin and paclitaxel in osteosarcoma and non-small cell 
lung cancer [126] and to sensitize anaplastic thyroid carcinoma cells to cisplatin [150]. 
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2-DG can be administered intravenously or orally with a blood half-life of 
approximately 90 minutes, and toxicity, mainly hypoglycemia-like symptoms, has in 
early clinical studies been transient [149]. Likely in part due to the unfavorable 
pharmacokinetics with rapid elimination of the drug, clinical trials have not been able 
to validate the promising preclinical findings [127, 149, 150].  
 
In conclusion, this study shows a platinum-potentiating effect of glycolysis inhibitor 2-
DG in ovarian cancer cell lines and tumor cells from ascites. Our results validate 
targeting glycolysis in serous EOC and also indicate the β-F1-ATPase:HSP60 ratio to 
be predictive of sensitivity to such combination treatment.  
 
 
5.2 PAPERS II AND III 
HSP60 predicts survival in advanced serous ovarian cancer  
and 
Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous 
ovarian cancer  
 
5.2.1 HSP60 
At both mRNA and protein levels, PFI and survival were significantly shorter in the 
HSP60 high expression group. The median interval from end of treatment to relapse 
was 4, 6 and 13 months for the mRNA high, intermediate and low expression groups 
(p=0.010), respectively, with corresponding 5 and 12 months for the groups with high 
and low protein expression (p=0.024). The median survival for the mRNA high, 
intermediate and low expression groups were 25 months, 35 months versus not yet 
reached (p=0.037). Accordingly, the median survival in the high and low protein 
expression groups were 31 and 55 months (p=0.016). In multivariate analyses, HSP60 
mRNA and protein expression were both verified to have independent impact on PFI 
and survival (Table 4). A subgroup analysis of the grade 3 serous tumors (n=40) 
showed higher HRs when including only these (OS: HR 3.8, 95% CI 1.3-11.0, PFI: HR 
4.8, 95% CI 1.9-12.0).  
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Table 4. Uni- and multivariate analyses of survival and platinum-free interval in 
relation to HSP60 mRNA and protein expression 
 
 Multivariate analysesa 
Method Endpoint HSP60 expression HR (95% CI) p-value 
Real time-
PCR (N=55) 
OS <0.50 (n=18) 
0.50-1.31 (n=18) 
>1.31 (n=19) 
1 
2.2 (0.9-5.6) 
3.4 (1.3-8.5) 
 
 
0.037 
PFI <0.50 (n=18) 
0.50-1.31 (n=18) 
>1.31 (n=19) 
1 
2.0 (0.9-4.2) 
3.3 (1.5-7.2) 
 
 
0.010 
IHC  
(N=54) 
OS <30% 3+ (n=17) 
≥30% 3+ (n=37) 
1 
3.2 (1.5-7.1) 
 
0.004 
PFI <30% 3+ (n=17) 
≥30% 3+ (n=37) 
1 
2.6 (1.3-5.3) 
 
0.008 
 
Abbreviations: HR=hazard ratio, CI=confidence interval, OS=overall survival, PFI=platinum-
free interval, IHC=immunohistochemistry. 
aMultivariate model with adjustment for age, FIGO stage, grade and postoperative residual 
tumor size 
 
All patients with low HSP60 levels responded to first line chemotherapy. Concordantly, 
the protein expression of this marker was shown significantly associated with treatment 
response (p=0.02). At the mRNA level, though, we found only a borderline significant 
association (p=0.055). 
 
5.2.2 GAPDH 
The median PFI was significantly shorter for patients with high GAPDH mRNA 
expression compared to cases with low expression (5.0 and 10.1 months, respectively, 
p=0.031). In univariate analysis, a high GAPDH mRNA was also found associated with 
shorter OS (p=0.015). However, in multivariate analysis, a high GAPDH remained 
significant only for shorter PFI (HR 2.1, 95% CI 1.0-4.5, p=0.043).  
 
Using IHC, we found no statistically significant differences in PFI or survival between 
groups with high or low GAPDH protein expression. GAPDH-reactivity was 
predominantly cytoplasmatic, but in 22 cases (41 %) we also found a nuclear 
localization of the enzyme. 
 
5.2.3 PKM2 
There were no statistically discernible differences in PFI or survival between groups 
with high or low PKM2 expression, neither at the mRNA-, nor at the protein level. The 
assessed PKM2-reactivity was cytoplasmatic, but in 11 cases (20 %) a nuclear 
localization of the protein was observed in mitotic cells. 
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5.2.4 ATP5B 
In univariate analysis, a high ATP5B mRNA expression predicted poor OS (p=0.025), 
but this finding did not remain significant at the multivariate level (HR 2.3, 95% CI 
1.0-5.3, p=0.062). Similarly, in univariate analysis, a high ATP5B protein expression 
predicted short PFI (p=0.039), but did not reach significance in the multivariate model 
(HR 1.7, 95% CI 1.0-3.2, p=0.075).  
 
5.2.5 BEC-index 
The median PFI was significantly longer in the group with high compared to the group 
with low BEC-index (9.8 and 5.3 months, respectively, p=0.028). Accordingly, 
multivariate analysis showed a high BEC-index mRNA to independently predict longer 
PFI (HR 0.47, 95% CI 0.23-0.95, p=0.035). Also, univariate analysis indicated a high 
BEC-index to predict longer survival (p=0.033), but it did not remain significant in 
multivariate calculations (HR 0.49, 95% CI 0.22-1.31, p=0.088). 
 
5.2.6 Discussion and conclusions 
Our data suggest high tumor HSP60 expression, at both mRNA and protein levels, to 
be indicative of early relapse and poor survival of HGSOC patients. We also show high 
GAPDH as well as low BEC-index based on mRNA to be associated with early disease 
progression. In addition, low HSP60 protein expression may predict response to first-
line platinum-based chemotherapy.  
 
Heat shock proteins are induced by endogenous or exogenous stress to promote cell 
survival and homeostasis. They predominantly function as chaperones for other cellular 
proteins. By ensuring the right conformation of these “client” proteins, they take part in 
the regulation of their downstream targets [151, 152]. Rapidly dividing malignant cells 
thus rely on chaperones for correct folding of oncoproteins, and HSP60 has been shown 
to have anti-apoptotic and pro-survival features [153-155]. For example, HSP60 
stabilizes apoptosis inhibitor survivin [156], inhibits mitochondrial permeability 
transition and caspase-dependent apoptosis [157], and has also been shown to play a 
role in the nuclear factor κΒ survival pathway [155].  
The specific mechanisms by which HSP60 mediate the observed poor prognosis and 
treatment-resistance in serous EOC remains unclear. However, it has previously been 
associated with platinum-resistance in ovarian carcinoma cell lines [158, 159]. Our 
results are also in accordance with findings in other malignancies, such as lung and 
prostate cancer [160-162].  
 
To our knowledge, this is the first study of metabolic markers in ovarian cancer 
patients, and the first publication evaluating the BEC-index at the mRNA level. Despite 
the limited study size, our results on GAPDH and BEC-index are in line with findings 
in other malignancies, such as breast, colon and lung cancer [128, 136, 137, 142, 144].  
The observed up-regulated GAPDH and low BEC-index in the early relapsing cases 
both reflect an increased dependence upon glycolysis in these tumors. These changes 
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are in accordance with the original Warburg hypothesis of a universal cancer cell 
glycolytic phenotype, and provide examples of the prognostic bearing of the metabolic 
alterations seen in malignancy. The fact that we did not, in this small patient cohort, 
find any independent impact on outcome for ATP5B- or PKM2 expression does not 
exclude these enzymes from playing a role in serous tumor aggressiveness. The data for 
all our included markers needs validation in a larger cohort before generalizing the 
results to all HGSOC.  
 
GAPDH has been widely used as housekeeping reference gene/protein, also in studies 
of cancer. However, our data, as well as previous findings by others [128], suggest it 
unsuitable as such for studies in malignancy. 
 
In conclusion, our results indicate that HSP60, GAPDH and BEC-index expression 
may be able to aid in identifying groups of advanced HGSOCs with different 
prognosis. In addition, HSP60 protein expression may be of value as predictive of 
response to first-line chemotherapy.  
 
 
5.3 PAPER IV 
Metabolic markers and HSP60 in chemonaïve serous solid ovarian cancer versus 
ascites  
 
5.3.1 Solid tumor versus ascites 
In contrast to our pre-study hypothesis, the mRNA expression of GAPDH, PKM2, 
ATP5B and HSP60 did not differ in pairwise comparison of serous solid tumor and 
corresponding malignant ascites. On the contrary, when examining the expression 
value distribution of solid tumor versus ascites tumor cells, there was not even a 
discernible trend towards an altered expression in detached cells. Thus, for all 
investigated metabolic markers, roughly half of the cases exhibited an equal or higher 
expression in ascites, with the other half accordingly showing a higher expression in 
solid tumor. 
 
5.3.2 Discussion and conclusion 
We are not aware of any other study having compared the expression of glycolytic and 
oxidative markers in a clinical material of solid tumors and corresponding effusions. 
Our results indicate that further reprogramming of glycolysis or oxidative 
phosphorylation is not a prerequisite for cancer cell survival after detachment.  
 
This study is too small to rule out potential alterations in mRNA expression of analyzed 
markers, but our very similar findings in the respective cell state argue against there 
being any. Also, a similar expression at the transcriptional level does not necessarily 
translate into activity of respective enzyme. However, we suggest that the highly 
malignant, progressed cell state of the solid advanced serous carcinoma may already 
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exploit its glycolytic and oxidative pathways maximally, making further changes in 
expression along disease progression difficult to detect. The major metabolic 
reprogramming in serous EOC would thus occur at an earlier stage.  
Above arguments might in principle also explain the similar HSP60 expression in 
compared adherent and detached cells. Supporting here presented findings, in a recent 
study of ascites cells spontaneously forming spheroids compared to single cells, we 
found no difference in HSP60 or ATP5B protein expression [163].  
 
A similar transcription of glycolytic and oxidative genes does not exclude changes in 
other metabolic pathways. Cancer cells can, when glucose availability is low, 
compensate by increasing their use of glutamine or serine as energy substrates [120, 
122, 164]. Whether ascites tumor cells enhance their use of alternative fuel remains 
unknown.  
 
In conclusion, our results on GAPDH, PKM2, ATP5B and HSP60 mRNA in advanced 
serous ovarian cancer indicate there being no major difference in expression of either 
marker in solid tumor compared to corresponding malignant ascites.  
 
 
5.4 CONSIDERATIONS IN CHOICE OF METHODS 
In paper I, we used a sulforhodamine B-based assay to study cell survival in vitro. In 
contrast to the alternative tetrazolium assays, the SRB assay does not depend upon cell 
enzymatic activity, which confers an advantage when studying cellular metabolic 
alterations. 
 
In paper II-III, we wanted to investigate the expression of a small group of markers and 
their association with outcome. Knowing that the expression of cellular molecules at 
the RNA and protein levels is not always concordant, we decided to study both.  
The quantitative real-time PCR method was well suited for the limited RNA analyses. 
We used SYBR Green™ for detection of PCR-products. This dye fluoresces when 
bound to all double-stranded DNA, which imposes a risk of signal also from 
contaminating DNA. However, when analyzing abundantly expressed genes, the 
proportion of signal from non-target DNA will be negligible. SYBR Green™ is thus 
not as specific as the alternative TaqMan-probe, but adequate when analyzing highly 
expressed genes (as in our studies). Also, our forward and reverse primers were 
localized in different exons, minimizing risk of transcription of contaminating DNA. 
 
For validation at the protein level, we chose to do immunohistochemistry. This is a 
method used in everyday clinical routine and the cost is manageable. Another obvious 
advantage is the availability of tissue blocks. In addition, IHC provides the possibility 
to discern the subcellular localization(s) of assessed proteins. The drawbacks of this 
method are its semi-quantitative nature and the risk of subjectivity in evaluation of 
slides. It is also a fairly insensitive method, in which small differences in staining are 
not discernible. To in part overcome this, digitalized procedures have been developed, 
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but these are costly and time-consuming and yet not applicable in the clinic. Also, the 
problem of subjectivity still remains.  
To reduce the error of subjectivity in our study, the evaluation of slides were done by 
three independent observers, blinded for clinical data.  
 
 
5.5 STATISTICAL PITFALLS  
Our study population is limited by its small size, and we cannot rule out a risk of 
misrepresentation because of sampling from the targeted study base (bias due to non-
participation). Results are therefore not directly generalizable to all HGSOC patients, 
but needs validation in a larger cohort. The close-to-perfect analysis would have 
included all patients undergoing surgery for advanced endometrioid or serous ovarian 
cancer during the study period. This scenario is difficult to achieve, however, since 
preoperative diagnostics are not always accurate and clinical logistics sometimes an 
obstacle.  
 
The risk of misclassification, i.e. measuring errors, is obvious when using a semi-
quantitative, possibly subjective method as IHC. In our studies, we have reduced this 
risk by setting up pre-defined measuring means and by being three independent 
observers, unaware of case records.  
Misclassification could also apply to clinical assessments, e.g. histopathological 
diagnose of EOC subtype and evaluations of response to treatment and progression. To 
decrease these potential errors, a subspecialized gynae-pathologist classified all cases 
and pre-defined modified RECIST- and GCIG criteria were applied for clinical 
evaluations. 
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6 GENERAL CONCLUSIONS 
 
Ø In ovarian cancer cells, glycolysis inhibitor 2-DG can potentiate the 
antiproliferative effects of concomitant platinum treatment, and the β-F1-
ATPase:HSP60 ratio might be predictive of sensitivity to such combination 
treatment.  
 
Ø HSP60 expression, at both mRNA and protein levels, may identify groups of 
advanced high-grade serous carcinomas with different prognosis. Also, HSP60 
protein expression may aid in prediction of resistance to first-line platinum-
based chemotherapy.  
 
Ø High GAPDH as well as low BEC-index mRNA is indicative of early disease 
progression in high-grade serous EOC, and these metabolic markers may thus 
also be of value in distinguishing patients with different prognosis. 
 
Ø Neither glycolytic GAPDH or PKM2, nor mitochondrial ATP5B or HSP60 
mRNA expression differ between solid high-grade serous cancer and 
corresponding malignant cells in ascites. These findings indicate that further 
reprogramming of glycolysis or oxidative phosphorylation is not a prerequisite 
for serous cancer cell survival after detachment. Also, possible future drugs 
targeting glycolysis should have equal effect in both solid tumor lesions and 
malignant ascites.  
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7 FUTURE PERSPECTIVES 
 
Epithelial ovarian cancer remains a disease usually detected after dissemination, and it 
still carries a poor prognosis. A more radical surgical approach has over the last decade 
somewhat improved survival, but more effective systemic treatment is badly needed. 
Since the various EOC subtypes are essentially different diseases, future developments 
in prognostication and treatment should focus on subgroup-specific phenotypic and 
molecular alterations.  
 
Over the last years, many trials have investigated the addition of targeting substances 
(e.g. inhibitors of VEGF, tyrosine kinases and PARP, see sections 1.6.4 and 1.8.1) to 
routine chemotherapy, and some of these have shown positive results. In the future, the 
addition also of drugs targeting malignant metabolic pathway alterations could further 
improve treatment efficacy.  
In the clinic, with a growing number of treatment options, it will be of vital importance 
to be able to better discriminate which patients who will gain from a certain toxic 
treatment, and who will not. Finding subgroup-specific prognostic and treatment 
predictive markers will make these decisions less difficult to make. Especially for the 
seemingly homogenous, large group of high-grade serous cancers, a growing number 
of studies indicate there being subgroups with very varying molecular alterations and 
prognosis [19, 23, 24]. 
 
In conclusion, our studies represent a few steps on the road towards better 
prognostication and personalized treatment of epithelial ovarian cancer. Targeting the 
various metabolic pathways could be a way of increasing treatment efficacy in this 
disease. Further exploration also of enzymes of glutaminolysis and combination 
treatment using inhibitors of more than one metabolic pathway thus provide additional 
options of study. 
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